Bioequivalence of a Fixed‐Dose Combination of Relugolix, Estradiol, and Norethindrone Acetate: An Open‐Label, Randomized, Fully Replicate Crossover Study in Healthy Postmenopausal Women Under Fasting Conditions
Clinical Pharmacology in Drug Development · 2026-06 · 15 (6)
DOI: 10.1002/cpdd.70076 ↗At a glance
Randomisierte kontrollierte Studie in Clinical Pharmacology in Drug Development, published online on 2026-06-19. Written by Ravi Kotadia and 6 co-authors. Institution: Medical Affairs and Clinical Research, Sun Pharma Laboratories Ltd., India. Major MEDLINE topics: Estradiol, Norethindrone, Norethindrone Acetate, Postmenopause. 23 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Uterine fibroids are the most common benign gynecological tumors, often causing heavy menstrual bleeding (HMB), anemia, and impaired quality of life. A fixed‐dose combination (FDC) of relugolix (40 mg), estradiol (1 mg), and norethindrone acetate (0.5 mg) was developed to address these limitations. This open‐label, randomized, two‐treatment, two‐sequence, four‐period, crossover bioequivalence study was conducted in 48 healthy postmenopausal women under fasting conditions. Participants received a single oral dose of either the RELUEASE (Sun Pharmaceutical Industries Limited, India) or the reference product (MYFEMBREE) (Patheon Inc., Mississauga, Ontario), with a 21‐day washout. Pharmacokinetics parameters were derived using non‐compartmental analysis. Bioequivalence assessment was performed using a linear mixed‐effects model applied to ln‐transformed pharmacokinetic parameters. A total of 39 participants completed all study periods. The point estimates and 90% confidence intervals (CIs), or the 95% upper bound for the pharmacokinetic parameters (C max and AUC) of relugolix, estradiol, norethindrone, and estrone met the predefined bioequivalence acceptance criteria. Six adverse events were reported, all mild, transient in nature, and resolving without sequelae. No clinically significant safety concerns were observed during the study. The relugolix/estradiol/norethindrone acetate FDC demonstrated bioequivalence to the globally approved reference product (MYFEMBREE) with comparable tolerability. This provides a safe, effective, reversible non‐surgical therapy for fibroid‐related HMB, fulfilling an unmet need beyond surgery.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Medical Affairs and Clinical Research, Sun Pharma Laboratories Ltd., India.
- Pharmacokinetics, CPP, Sun Pharmaceutical Industries Ltd., India.
Cite
APA
Kotadia, R., Kumar, S., Khuroo, A., Dharmadhikari, S., Shahi, P., Narayana, G. N. V. S. S., & Reyar, S. (2026). Bioequivalence of a Fixed‐Dose Combination of Relugolix, Estradiol, and Norethindrone Acetate: An Open‐Label, Randomized, Fully Replicate Crossover Study in Healthy Postmenopausal Women Under Fasting Conditions. Clinical Pharmacology in Drug Development, 15(6). https://doi.org/10.1002/cpdd.70076
Vancouver
Kotadia R, Kumar S, Khuroo A, Dharmadhikari S, Shahi P, Narayana GNVSS, et al. Bioequivalence of a Fixed‐Dose Combination of Relugolix, Estradiol, and Norethindrone Acetate: An Open‐Label, Randomized, Fully Replicate Crossover Study in Healthy Postmenopausal Women Under Fasting Conditions. Clinical Pharmacology in Drug Development. 2026;15(6). doi:10.1002/cpdd.70076
BibTeX
@article{Kotadia2026,
author = {Kotadia, Ravi and Kumar, Sudershan and Khuroo, Arshad and Dharmadhikari, Shruti and Shahi, Pradeep and Narayana, Goru N V S Satya and Reyar, Simrit},
title = {Bioequivalence of a Fixed‐Dose Combination of Relugolix, Estradiol, and Norethindrone Acetate: An Open‐Label, Randomized, Fully Replicate Crossover Study in Healthy Postmenopausal Women Under Fasting Conditions},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {6},
doi = {10.1002/cpdd.70076}
}
EUVIMED